EPA:SAN 25 May 2026 - 28 June 2026

CSL stock eyes new test as Sanofi enters picture after tough year
··

CSL stock eyes new test as Sanofi enters picture after tough year

CSL Ltd. is back in focus for Thursday’s Australian session, as Sanofi put pledges to EU regulators about its actions toward CSL Seqirus’s Fluad flu shot. Investors are watching the latest on the vaccine development. The stock finished Wednesday up 0.27% at A$124.30. The S&P/ASX 200, which tracks big listed names and is a key local market benchmark for institutions, slipped 0.21% to 8,785.10.
July 8, 2026
CSL (ASX:CSL) in focus for Monday as shares face test after Sanofi probe, Tavneos setback
··

CSL (ASX:CSL) in focus for Monday as shares face test after Sanofi probe, Tavneos setback

CSL Limited heads into this week after shares ended at A$114.87 on Friday, dropping 2.36%. The session saw ASX normal cash trading run from about 09:59:45 to 16:00 Sydney time. CSL slipped 1.2% for the week, measured from the June 19 close. Trading stayed volatile: the stock dropped to A$110.89 on Monday, then jumped to A$118.88 by Thursday. With 478.91 million shares out, that's an A$7.99 trading band, or about A$3.8 billion in market cap.
June 28, 2026